3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
6
Phase 2
5
Phase NA
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma, Large B-Cell, Diffuse
9
Hodgkin Disease
7
Sarcoma
6
Lymphoma
6
Testicular Neoplasms
5
Testicular Germ Cell Tumor
5
Ovarian Neoplasms
5
Osteosarcoma
5
Lymphoma, Follicular
5
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Burkitt Lymphoma
4
Recurrence
3
Lymphoma, Large-Cell, Immunoblastic
3
Immunoblastic Lymphadenopathy
3
Central Nervous System Neoplasms
3
Waldenstrom Macroglobulinemia
2
Teratoma
2
Solitary Fibrous Tumors
2
Small Cell Lung Carcinoma
2
Sarcoma, Clear Cell
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemangiosarcoma
2
Hemangioendothelioma, Epithelioid
2
Dendritic Cell Sarcoma, Interdigitating
2
Interventions
Temozolomide
8
Irinotecan
7
Vincristine
6
Nivolumab
2
temsirolimus
1
talazoparib
1
surufatinib
1
sonidegib
1
silmitasertib
1
regorafenib
1
prexasertib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
lenvatinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
irinotecan sucrosofate
1
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
1
ganitumab
1
eribulin
1
efineptakin alfa
1
dostarlimab
1
dinutuximab
1
copanlisib
1
bempegaldesleukin
1
atezolizumab
1
adavosertib
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rhabdomyosarcoma
×
Ifosfamide
×
Clear all
NCT04625907
2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2
Recruiting
1,672 enrolled